Eliquis 5 mg film-coated tablets clinical trials
7 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
This study looks at a new drug, abelacimab, compared to a standard drug, apixaban, for treating blood clots in veins (VTE) in people with cancer. The main goal is to see which drug is better at preventing new clots and causing less bleeding over six months.
For: venous thromboembolism (VTE)Latvia · Ireland · Italy - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Randomised, crossover bioequivalence clinical trial of apixabán 5 mg film coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.
This study is testing if a new version of the blood thinner apixaban works the same way as the original. Healthy adults take a single dose of both medicines to see how they behave in the body.
For: Healthy volunteersSpain - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions
This study is testing if two versions of a blood-thinning medicine called apixaban (often known as Eliquis) work the same way in healthy people. Researchers want to ensure the body absorbs both medicines in a similar fashion. It's an early-stage study to check drug absorption.
For: thromboembolismSpain - Ongoing, recruitingTherapeutic use (Phase IV)
COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
This study compares two common blood-thinning medicines, Rivaroxaban (Xarelto) and Apixaban (Eliquis), for treating blood clots (venous thromboembolism). Researchers want to see which medicine causes fewer serious bleeding side effects for patients already on these treatments.
For: Acute Venous ThromboembolismIreland - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
RANDOMISED, CROSSOVER BIOEQUIVALENCE CLINICAL TRIAL OF APIXABAN 5 MG CAPSULES VS APIXABAN 5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING CONDITIONS
This study compares different forms of a blood-thinning medicine called apixaban (found in Eliquis) in healthy volunteers. We want to see if a new capsule version works the same way as the current tablet form when taken on an empty stomach. This helps ensure new medicines are safe and effective.
For: thrombosisSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
This study is testing a new medication called asundexian against a standard treatment (apixaban) to see how well it prevents strokes or serious blood clots in people with atrial fibrillation, a type of irregular heartbeat. It's also looking at how safe the new drug is.
For: Prevention of stroke or systemic embolism in atrial fibrillationFinland · Norway · Denmark - AuthorisedTherapeutic confirmatory (Phase III)
MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study. An international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.
This study, called MOSES, is looking at how best to prevent another stroke in people who have recently had one. It's testing if a specific blood test, together with different blood-thinning medicines, can help doctors choose the best treatment to stop future strokes.
For: Acute ischemic strokeGreece · Spain